BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

CEO

Mr. Kenneth Mulvany

Employees

180

Country

Luxembourg

ISIN

LU2355630455

WKN

000A3CTVP

Listings

STU

2XA.STU

0 Comments

Share your thoughts

FAQ

What is Odyssey Acquisition. stock price today?▼

The current price of 2XA.STU is €0.57 EUR — it has increased by +7.2% in the past 24 hours. Watch Odyssey Acquisition. stock price performance more closely on the chart.

What is Odyssey Acquisition. stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Odyssey Acquisition. stocks are traded under the ticker 2XA.STU.

How many employees does Odyssey Acquisition. have?▼

As of September 04, 2026, the company has 180 employees.

In which sector is Odyssey Acquisition. located?▼

Odyssey Acquisition. operates in the Health & Wellness sector.

When did Odyssey Acquisition. complete a stock split?▼

Odyssey Acquisition. has not had any recent stock splits.

Where is Odyssey Acquisition. headquartered?▼

Odyssey Acquisition. is headquartered in London, Luxembourg.